Sensorion S.A.
ALSEN.PA
Get informed when a big investor buys or sells
+ FollowMarket Cap$35.8M
Close$
$3.23
44.9% downside
Current Fair Value
44.9% downsideOvervalued by 44.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $35.80 Million |
|---|---|
| Enterprise Value | $13.64 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.9 |
| Beta | 0.41 |
| Outstanding Shares | 10,309,000 |
Return
| Return on Equity | -13.59% |
|---|---|
| Return on Assets | -3.54% |
| Return on Invested Capital | 4.03% |
Valuation & Multiples
| P/E Ratio | -1.38 |
|---|---|
| PEG | 0.76 |
| Price to Sales | 0.0 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | 0.25 |
| Enterprise Value to EBIT | 8.94 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 1.68 |
| Debt to Equity | 1.53 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 23, 2026
EPS Estimate
$-1.90
Average shareholder expectationRevenue Estimate
$1.97 M
Average shareholder expectationNext Earnings Call
Expected Date
March 18, 2027
EPS Estimate
$-2.01
Average shareholder expectationRevenue Estimate
$1.99 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sensorion S.A.
66 employees
CEO: Frédéric Chéreau Sensorion SA is a clinical-stage biopharmaceutical firm based in Montpellier, France, specializing in the development of therapies for inner ear disorders. Their key initiatives include gene therapy programs: OTOF-GT, designed to restore...